Bellevue Group AG Sells 7,500 Shares of Bicycle Therapeutics plc (NASDAQ:BCYC)

Bellevue Group AG lessened its position in Bicycle Therapeutics plc (NASDAQ:BCYC) by 37.5% during the 1st quarter, Holdings Channel reports. The firm owned 12,500 shares of the company’s stock after selling 7,500 shares during the quarter. Bellevue Group AG’s holdings in Bicycle Therapeutics were worth $311,000 at the end of the most recent reporting period.

Other large investors have also made changes to their positions in the company. China Universal Asset Management Co. Ltd. boosted its position in Bicycle Therapeutics by 489.2% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 4,001 shares of the company’s stock valued at $72,000 after buying an additional 3,322 shares in the last quarter. PNC Financial Services Group Inc. acquired a new position in shares of Bicycle Therapeutics in the 4th quarter worth approximately $137,000. PDS Planning Inc bought a new stake in Bicycle Therapeutics during the 1st quarter worth approximately $210,000. Concurrent Investment Advisors LLC acquired a new stake in Bicycle Therapeutics during the 1st quarter valued at $543,000. Finally, Woodstock Corp raised its position in Bicycle Therapeutics by 16.3% in the 1st quarter. Woodstock Corp now owns 24,981 shares of the company’s stock valued at $622,000 after purchasing an additional 3,502 shares during the last quarter. Institutional investors own 86.15% of the company’s stock.

Insider Transactions at Bicycle Therapeutics

In other Bicycle Therapeutics news, CEO Kevin Lee sold 3,194 shares of the company’s stock in a transaction that occurred on Wednesday, July 3rd. The shares were sold at an average price of $19.64, for a total value of $62,730.16. Following the completion of the sale, the chief executive officer now owns 384,076 shares of the company’s stock, valued at $7,543,252.64. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In the last ninety days, insiders sold 4,555 shares of company stock worth $89,460. 8.50% of the stock is currently owned by company insiders.

Analyst Ratings Changes

Several analysts have recently commented on BCYC shares. Needham & Company LLC restated a “buy” rating and set a $43.00 target price on shares of Bicycle Therapeutics in a report on Wednesday, April 10th. HC Wainwright reaffirmed a “buy” rating and issued a $55.00 target price on shares of Bicycle Therapeutics in a research note on Friday, May 3rd. One analyst has rated the stock with a hold rating and six have issued a buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $46.86.

Bicycle Therapeutics Trading Down 4.7 %

Shares of BCYC traded down $1.16 on Monday, reaching $23.35. 34,756 shares of the company’s stock were exchanged, compared to its average volume of 332,441. The business has a 50 day moving average price of $22.07 and a two-hundred day moving average price of $22.13. Bicycle Therapeutics plc has a 12 month low of $12.54 and a 12 month high of $27.24. The stock has a market capitalization of $998.89 million, a P/E ratio of -5.35 and a beta of 0.94. The company has a current ratio of 10.42, a quick ratio of 10.42 and a debt-to-equity ratio of 0.09.

Bicycle Therapeutics (NASDAQ:BCYC) last posted its quarterly earnings results on Thursday, May 2nd. The company reported ($0.62) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.25) by $0.63. Bicycle Therapeutics had a negative return on equity of 49.35% and a negative net margin of 404.14%. The company had revenue of $19.53 million for the quarter, compared to the consensus estimate of $6.06 million. The business’s revenue for the quarter was up 298.9% on a year-over-year basis. Research analysts anticipate that Bicycle Therapeutics plc will post -4.44 earnings per share for the current year.

Bicycle Therapeutics Profile

Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. Its product pipeline comprising BT8009, a bicycle toxin conjugate (BTC) which is in phase I/II/III clinical trial for the treatment of high nectin-4 expressing tumors; BT5528, a BTC which is in phase I/II clinical trial for the treatment of Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle TICA molecule which is in phase I/II targeting Nectin-4 and agonizing CD137; and BT7455, a Bicycle TICA molecule targeting Ephrin type A receptor 2 and CD137 and is in preclinical trial.